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a simple and not very costly operation with a relatively fast
recovery.
In conclusion, the advantages of this 2-stage surgical technique
are the reduction of the extent and costs of the second-stage
operation along with the advantages of reconstruction with a
gastric tube via the posterior mediastinum.
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The implantation of a left ventricular assist device(LVAD) both as a bridge to transplantation and asdestination therapy is being used with increasing fre-quency in patients with end-stage heart failure. Two
main types of LVADs are currently being used: pulsatile and
continuous flow devices. Continuous devices are much smaller and
produce a continuous flow with either an axial or centrifugal flow
pump. These devices fill during both the systolic and diastolic
phase.1
Despite the overall success of LVAD support and the advances
in design in both types of devices, infection continues to be a
common morbidity of mechanical circulatory support and remains
a serious threat to the long-term survival of patients using
LVADs.2,3 This study was designed to determine the differences in
infection rates between patients with puslatile pumps (HeartMate I;
Thermo Cardiosystems, Inc, Woburn, Mass) versus those with
axial flow devices (HeartMate II or DeBakey; MicroMed Tech-
nology, Inc, Houston, Tex).
Patients and Methods
We retrospectively reviewed the case histories of 92 patients
undergoing LVAD implantation at a single center between Octo-
ber 2003 and April 2006. This analysis captured the first 27 axial
flow device implants at our center, as well as every HeartMate I
device implanted during the same interval. LVADs were classified
as pulsatile (n  65) or continuous flow (n  27). Local device
infection was defined by clinical signs of infection with positive
culture(s) from the abdominal wound, driveline, pocket, or pump.
The 2 test was used to analyze the associations between device
type and categorical variables (device infections, gender, preoper-
ative history of diabetes or hypertension, bridge-to-transplant rate,
and post-implant 1-year survival), and the nonparametric Mann–
Whitney test was used to analyze associations between device type
and continuous variables (age, height, body surface area [BSA],
and body mass index [BMI]).
Results
Findings are summarized in Table 1. There were no significant
differences between pulsatile and continuous device groups with
respect to age, gender, height, or preoperative history of diabetes
or hypertension. BSA (2.0 vs 1.89; P  .035) and BMI (28.6 vs
24.9; P  .009) were significantly higher in patients with pulsatile
devices. Patients with pulsatile devices were more likely to have an
LVAD-related infection (18/65 vs 1/27, 27.7% vs 3.7%; P 
.010), in particular pocket infections (10/65 vs 0/27, 15.4% vs 0%;
P  .031) and wound infections (10/65 vs 0/27, 15.4% vs 0%;
P  .031). Of note, the rates of driveline infection (9/65 vs
2/27, 13.8% vs 7.4%; P  .271) and pump endocarditis (2/62 vs
1/26, 3.2% vs 3.7%; P  .999) were comparable between the
two groups. Device infections had no effect on bridge-to-
transplant rate (15/18 vs 39/56, 83.3% vs 69.6%; P  .364) or
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postimplant 1-year survival (13/19 vs 50/71, 68.4% vs 70.4%;
P  .999) in either group.
Discussion
Differences in infection rates between pulsatile and continuous
flow LVADs may be a reflection of differences in device design.
Continuous flow devices are smaller and do not have compliance
chambers, polyurethane membranes, or prosthetic valves that pul-
satile devices have.4 The larger implanted surface and the pooling
of fluid that may surround the pulsatile devices promote microbial
adhesion and growth.2 Furthermore, continuous flow devices need
only a small pump pocket and do not require a great deal of
surgical dissection. These characteristics collectively may explain
the low infection rate. This difference in device size underlies the
significant difference in BMI and BSA between the two groups;
smaller patients who are not candidates for the HeartMate I LVAD
are often able to accommodate the comparatively smaller contin-
uous flow pumps.
Results from this single-center analysis support the hypothesis
that continuous flow LVADs have reduced infection rates. Sur-
prisingly, there was no difference in pump endocarditis. Perhaps
this can be attributed to a definition of infection that is too
stringent—broad-spectrum antibiotic use may suppress bacterial
growth and lead to false negative cultures in the setting of true
device infection. Alternatively, this finding may reflect improved
infection control in the post-REMATCH* era. Optimal implanta-
tion techniques, tight glucose control, and meticulous surgical site
care may all contribute to decreased LVAD infection rates.
It is not surprising that there is no significant difference in
driveline infection rates between pulsatile and continuous flow
LVADs, because both devices require an abdominal exit site that
connects the pump to an external power source. The high incidence
of driveline infection in the literature highlights the importance
of improving on currently used technology. Furthermore, deep
driveline tract infections often result in pocket and/or device
infections that may be refractory to medical treatment.5 Further
development of transcutaneous energy transmission systems
may further reduce infection rates by eliminating the need for
drivelines.
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*REMATCH  Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure.
TABLE 1. Demographic profile and infection rates for all









Age (y) 51.8  13.3 55.1  12.8 NS
Female 10/65 (15.4%) 5/27 (18.5%) NS
Height (cm) 174.5  8.6 173.7  8.5 NS
Weight (kg) 87.0  20.0 75.2  17.7 .016
BMI 28.6  6.1 24.9  5.5 .009
BSA 2.0  0.3 1.89  0.25 .035
Diabetes 20/65 (30.8%) 10/27 (37.0%) NS
Hypertension 24/65 (36.9%) 9/27 (33.3%) NS
MCS (d) 133.6  124.1 130.1  117.8 NS
Infection type
LDI 18/65 (27.7%) 1/27 (3.7%) .010
Driveline 9/65 (13.8%) 2/27 (7.4%) NS
Pocket 10/65 (15.4%) 0/27 (0%) .031
Wound 10/65 (15.4%) 0/27 (0%) .031
Bacteremia 17/65 (26.2%) 7/27 (25.9%) NS
Pump endocarditis 2/62 (3.2%) 1/27 (3.7%) NS
Sepsis 6/62 (9.7%) 1/26 (3.8%) NS
BMI, Body mass index; BSA, body surface area; MCS, mechanical circu-
latory support; LDI, local device infection; NS, not significant.
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